Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2020 | Immunotherapy approaches for NMIBC

Peter Black • 19 Jul 2020
EAU 2020
Bladder Cancer Genitourinary Cancer Antibodies Nadofaragene firadenovec Oportuzumab monatox Pembrolizumab

Peter Black, MD, FACS, FRCSC, of the University of British Columbia, Vancouver, Canada, discusses novel immunotherapy approaches for non-muscle invasive bladder cancer (NMIBC), including the approval of pembrolizumab for this indication as well as the novel antibody-drug conjugate, oportuzumab monatox. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Peter Black

3:35
Genomic subtyping in bladder cancer
Peter Black • 19 Jul 2020
2:48
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
Peter Black • 8 Feb 2018
1:52
Can atezolizumab succeed where BCG fails in bladder cancer?
Peter Black • 8 Feb 2018
1:08
Systemic treatments for non-muscle invasive bladder cancer
Peter Black • 8 Feb 2018

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals